ArticleImmunity, inflammation and disease2025
Amphiregulin Promotes Proliferation and Migration of the Damaged Endothelial Cells in Kawasaki Disease Cell Models.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesAmphiregulin (Areg), a member of the epidermal growth factor family, plays a critical role in tissue repair, inflammation, and immunity. Macrophages are an important source of Areg and are also among the key immune cells activated in Kawasaki disease (KD). Despite this, the role of Areg in KD has not been studied. Therefore, this study aims to investigate the expression of Areg in a KD model and to elucidate its effects on injured endothelial cells using a KD cell model.
methodsThe serum of LCWE-induced KD mouse model was measured by ELISA. RAW264.7 cells were stimulated with LCWE, and the supernatant was collected. Then, MCAECs were treated with LCWE-induced RAW264.7 cells conditioned medium (RAW-CM) to simulate inflammatory damage in KD endothelial cells.
resultsOur study showed that the serum level of Areg increased in LCWE-induced mouse model. In vitro, LCWE increased the expression and secretion of Areg in RAW264.7 macrophages, an effect that was inhibited by ADAM-17 blockade. The conditioned medium (CM) from LCWE-stimulated RAW264.7 cells (RAW-CM) enhanced the proliferative capacity of endothelial cells, an effect that was partially inhibited by Areg antibodies. Recombinant Areg promoted the proliferation and migration of damaged endothelial cells, effects that were dependent on the activation of the AKT and ERK signaling pathways.
conclusionThis study demonstrates that serum Areg level increased in LCWE-induced KD mouse model, and Areg promoted proliferation and migration abilities of injured endothelial cells. Our work suggests that Areg may be one of the reasons for the repair of injured endothelial cells in LCWE model vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.